Bio

Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020, 2021 and 2022, named Top Female Venture Capitalist in China by Forbes in 2022. She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), Venus MedTech (HKSE:2500), CanSino Biologics (SSE:688185; HKSE:6185), New Horizon Health (HKSE:6606), dMed, Chain Medical Labs, Berry Oncology, Belief BioMed, Valgen among others. Her other investments include Gan & Lee (SSE:603087), Aeonmed Medical, Berry Genomics (SZSE:000710), Broncus, CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Wuxi Leiming, MEDx, Cure Genetics, SinoCell Tech (SSE:688520), Apollomics, Sino United, Schrödinger (NASDAQ:SDGR) , Jacobio (HKSE:1167), Hope Medicine, Insilico Medicine, Zhenge among others. Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (“HKEX”) and Hong Kong Palace Museum.